Immunovant Shares Results from Proof-of-Concept Study of Imeroprubart in Cutaneous Lupus

Immunovant, a clinical-stage immunology company developing targeted therapies for autoimmune diseases, has announced topline results from a proof-of-concept study evaluating treatment imeroprubart (IMVT-1402) in people with cutaneous lupus erythematosus (CLE). The study did not meet its primary endpoint, with no statistically significant difference in the percent change from baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) score at week 12. 

The randomized, double-blind, placebo-controlled study enrolled 57 adults with CLE and evaluated imeroprubart compared with placebo over 12 weeks. Positive numerical trends favoring imeroprubart over placebo were observed on multiple other endpoints, and patients with deeper reductions in IgG levels were more likely to have improved clinical responses. Immunovant reported that the investigational therapy demonstrated a favorable safety and tolerability profile consistent with previous studies. 

Based on the results and the current treatment development landscape, Immunovant said it will discontinue development of imeroprubart in CLE. While this program will not move forward in CLE, findings from clinical studies such as this can help contribute to the broader understanding of lupus and inform future research as scientists continue working toward new and more effective treatment options. Immunovant remains focused on rapidly advancing the clinical development of therapies across a range of autoimmune diseases with significant unmet need. 

Education from this trial was supported by the Lupus Foundation of America's Research Accelerated by You Lupus Registry. 

Read the announcement